1-3 of 3
Wenzhong Guo
Close
Sort by
Journal Articles

Development of CD19 CAR Engineered Human Placental CD34 + -Derived Natural Killer Cells (CAR19-CYNK) As an Allogeneic Cancer Immunotherapy

Marina Gergues, Irene Raitman, Joseph Gleason, Valentina Rousseva, Shuyang He, William Van Der Touw, Qian Ye, Lin Kang, Yanliang Zhang, Chin-I Pai, Wenzhong Guo, Henry Ji, Robert Hariri, Xiaokui Zhang
Journal: Blood
Blood (2021) 138 (Supplement 1): 2779.
https://doi.org/10.1182/blood-2021-150593
Published: 2021
Journal Articles

Development of an Allogeneic Anti-Bcma T Cell Therapy Utilizing a Novel Dimeric Antigen Receptor (DAR) Structure

Bei Bei Ding, PhD, John Dixon Gray, PhD, Nan Zhang, Yanliang Zhang, PhD, Xia Cao, MSc, Irina Krapf, MSc, Qingdong Mark Deng, Angel Wei, MD, Jerome B. Zeldis, MD PhD, Robert D. Knight, MD, Gunnar F. Kaufmann, PhD, Henry Ji, PhD, Wenzhong Guo, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1942.
https://doi.org/10.1182/blood-2019-131892
Published: 2019
Journal Articles

Development of a Genetically-Engineered Allogeneic Anti-CD38 T Cell Therapy Utilizing a Novel Antigen Receptor Structure

Bei Bei Ding, PhD, John Dixon Gray, PhD, Irina Krapf, MSc, Yanliang Zhang, PhD, Nan Zhang, Qingdong Mark Deng, Angel Wei, MD, Robert D. Knight, MD, Jerome B. Zeldis, MD PhD, Gunnar F. Kaufmann, PhD, Henry Ji, PhD, Wenzhong Guo, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4444.
https://doi.org/10.1182/blood-2019-131586
Published: 2019